Unknown

Dataset Information

0

CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.


ABSTRACT: Although inhibitors targeting tumor angiogenic pathway have provided improvement for clinical treatment in patients with various solid tumors, the still very limited anti-cancer efficacy and acquired drug resistance demand new agents that may offer better clinical benefits. In the effort to find a small molecule potentially targeting several key pathways for tumor development, we designed, discovered and evaluated a novel multi-kinase inhibitor, CS2164. CS2164 inhibited the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFR? and c-Kit), mitosis-related kinase Aurora B and chronic inflammation-related kinase CSF-1R in a high potency manner with the IC50 at a single-digit nanomolar range. Consequently, CS2164 displayed anti-angiogenic activities through suppression of VEGFR/PDGFR phosphorylation, inhibition of ligand-dependent cell proliferation and capillary tube formation, and prevention of vasculature formation in tumor tissues. CS2164 also showed induction of G2/M cell cycle arrest and suppression of cell proliferation in tumor tissues through the inhibition of Aurora B-mediated H3 phosphorylation. Furthermore, CS2164 demonstrated the inhibitory effect on CSF-1R phosphorylation that led to the suppression of ligand-stimulated monocyte-to-macrophage differentiation and reduced CSF-1R+ cells in tumor tissues. The in vivo animal efficacy studies revealed that CS2164 induced remarkable regression or complete inhibition of tumor growth at well-tolerated oral doses in several human tumor xenograft models. Collectively, these results indicate that CS2164 is a highly selective multi-kinase inhibitor with potent anti-tumor activities against tumor angiogenesis, mitosis and chronic inflammation, which may provide the rationale for further clinical assessment of CS2164 as a therapeutic agent in the treatment of cancer.

SUBMITTER: Zhou Y 

PROVIDER: S-EPMC5378272 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.

Zhou You Y   Shan Song S   Li Zhi-Bin ZB   Xin Li-Jun LJ   Pan De-Si DS   Yang Qian-Jiao QJ   Liu Ying-Ping YP   Yue Xu-Peng XP   Liu Xiao-Rong XR   Gao Ji-Zhou JZ   Zhang Jin-Wen JW   Ning Zhi-Qiang ZQ   Lu Xian-Ping XP  

Cancer science 20170307 3


Although inhibitors targeting tumor angiogenic pathway have provided improvement for clinical treatment in patients with various solid tumors, the still very limited anti-cancer efficacy and acquired drug resistance demand new agents that may offer better clinical benefits. In the effort to find a small molecule potentially targeting several key pathways for tumor development, we designed, discovered and evaluated a novel multi-kinase inhibitor, CS2164. CS2164 inhibited the angiogenesis-related  ...[more]

Similar Datasets

| S-EPMC4622528 | biostudies-literature
| S-EPMC5362808 | biostudies-literature
| S-EPMC3848935 | biostudies-literature
| S-EPMC3636692 | biostudies-literature
| S-EPMC6019900 | biostudies-other
| S-EPMC2760204 | biostudies-literature
| S-EPMC6376031 | biostudies-literature
| S-EPMC3057563 | biostudies-literature
| S-EPMC3346683 | biostudies-other
| S-EPMC4889718 | biostudies-literature